Introduction
============

Non-typhoidal *Salmonella enterica* (NTS) are one of the most important etiological agents of foodborne diarrheal diseases in humans worldwide and cause an estimated 80.3 million foodborne illnesses a year ([@B19]). Although most cases of salmonellosis are self-limiting episodes of gastro-enteritis, severe cases of infection, including bacteremia and meningitis require antimicrobial treatment. Ciprofloxacin is a common first-line antimicrobial for treating salmonellosis but because fluoroquinolones are not used for treating children, β-lactams (ampicillin or third-generation cephalosporins) are of equal importance ([@B20]). Multidrug-resistant (MDR) NTS is associated with higher morbidity and mortality outcomes compared to drug-susceptible strains and is a major public health concern ([@B21]). *Salmonella enterica* subsp. *enterica* serovar Infantis (*S*. serovar Infantis) has emerged as the fourth most common serovar causing human salmonellosis in Europe, with 1,846 cases reported by the EU/EEA countries in 2014 ([@B10]). Poultry, especially from layer and broiler farms, as well as pigs are the main animal reservoirs for *S.* serovar Infantis ([@B23]). This serovar is also dominant in broiler meat, accounting for 35.9% of all *Salmonella* isolates reported from EU countries in 2014 ([@B10]). Over the last few years, antimicrobial resistance has emerged in *S*. serovar Infantis isolates from human and animal sources in various European countries and consequently, this serovar, together with *S*. Kentucky, contributes significantly to the numbers of MDR *Salmonella* in Europe ([@B22]; [@B9]). Closely related MDR clones of *S*. serovar Infantis have disseminated among broiler populations and associated animal growing environments, ultimately being disseminated into the food chain and then into humans in European countries such as Hungary, Poland and Austria ([@B23]). Isolates belonging to these clones are characterized by their resistance to nalidixic acid, sulfamethoxazole, streptomycin and tetracycline (NaSSuT). Recently, resistance to third generation cephalosporins has emerged in *S*. serovar Infantis isolates in Italy, due to the circulation of an extended-spectrum β-lactamase (ESBL) producing, MDR clone with additional reduced susceptibility to ciprofloxacin ([@B11]). The spread of MDR *S*. serovar Infantis clones throughout the food production system (mainly poultry and poultry meat) and in humans is highly worrisome and warrants improved understanding of its epidemiology. In Switzerland, *S*. serovar Infantis ranks among the top five of *Salmonella* serovars registered by the National Centre for Enteropathogenic Bacteria and Listeria (NENT). However, currently no data on antimicrobial resistance patterns or clonal relationships of the isolates exist, despite its clinical importance.

The aim of this study was to characterize a collection of 520 *S*. serovar Infantis strains isolated from food (poultry meat), human infections and environmental sources from the years 2010, 2013 and 2015 in Switzerland (i) by determining their phenotypic antibiotic resistance profiles using the disk diffusion method and (ii) by assessing genotypic characteristics and clonal relatedness using molecular methods including pulsed-field gel electrophoresis (PFGE), PCR, and whole genome sequencing (WGS).

Materials and Methods {#s1}
=====================

Bacterial Strains
-----------------

A total of 520 non-duplicate *S*. serovar Infantis isolates from human infections (*n* = 84), poultry meat (*n* = 418) and other sources (*n* = 18) were collected during 2010, 2013 and 2015 at the National Centre for Enteropathogenic Bacteria and Listeria (NENT), Switzerland. The isolates had been forwarded by hospitals, diagnostic laboratories or surveillance programs of retail markets and food or feed producing facilities for final species-level identification according to the White-Kauffmann-Le Minor scheme ([@B13]).

Antimicrobial Susceptibility Testing
------------------------------------

Antimicrobial susceptibility testing was performed using the disk-diffusion method and the antibiotics ampicillin (AM), amoxicillin-clavulanic acid (AMC), cefotaxime (CTX), nalidixic acid (Na), ciprofloxacin (CIP), gentamicin (GM), kanamycin (K), streptomycin (S), sulfamethoxazole (Su), trimethoprim (TMP), tetracycline (T), and chloramphenicol (C) (Becton Dickinson, Heidelberg, Germany). Results were interpreted according to Clinical and Laboratory Standards Institute (CLSI) performance standards ([@B8]). For sulfamethoxazole, for which breakpoints are not listed separately from trimethoprim, an inhibition zone of ≤10 mm was interpreted as resistant. Isolates displaying resistance to three or more classes of antimicrobials (counting β-lactams as one class) were defined as multidrug-resistant (MDR). Synergistic effects between AMC and CTX were regarded as an indication of the presence of an ESBL producer ([@B16]).

Detection and Characterization of Extended-Spectrum β-Lactamase (*bla*) Genes
-----------------------------------------------------------------------------

Putative ESBL producers were grown on Brilliance^TM^ESBL agar (Oxoid, Hampshire, United Kingdom). The presence of *bla*~ESBLs~ was confirmed by PCR by screening for *bla*~TEM~, *bla*~SHV~, and *bla*~CTX-M~ alleles belonging to CTX-M groups 1, 2, 8, 9, and 25 as described previously ([@B29]; [@B12]; [@B30]). Synthesis of primers and DNA custom sequencing was carried out by Microsynth (Balgach, Switzerland) and nucleotide sequences were analyzed with CLC Main Workbench 6.6.1. For database searches the BLASTN program of NCBI^[1](#fn01){ref-type="fn"}^ was used.

Pulsed-Field Gel Electrophoresis
--------------------------------

Pulsed-field gel electrophoresis was performed according to the PulseNet protocol of the Centers for Disease Control and Prevention (CDC)^[2](#fn02){ref-type="fn"}^, using the restriction enzyme *XbaI* (Roche, Mannheim, Germany) and *Salmonella* serovar Braenderup strain H9812 (ATCC BAA 664) as the reference strain. Restricted DNA was separated in a 1% agarose gel (BioRad, Cressier, Switzerland) at 12°C for 20 h at 6 V/cm under linear ramp with switch times from 2 to 64 s and 120° included angle using a CHEF-DR III system (BIO-RAD, Munich, Germany). Gels were stained with ethidium bromide and visualized under UV light with Gel Doc (BIO-RAD, Munich, Germany). GelCompar II software (Applied Maths NV, Sint-Martens-Latem, Belgium) was used for analysis. Pairwise similarities between the *XbaI* PFGE patterns were calculated by the DICE similarity coefficient. Clustering was based on the unweighted pair-group method with averages, setting tolerance at 1% and optimization at 0.5%.

Whole Genome Sequencing
-----------------------

Whole genome sequencing was performed with a representative subset of 32 isolates selected with regard to their PFGE pattern, source, year of isolation or presence of *bla*~CTX-M-65~. DNA extraction was performed with the Wizard^®^ Genomic DNA Purification Kit according to the manufacturers protocol (Promega AG, Dübendorf, Switzerland). Sequencing was performed on a MiSeq sequencer (Illumina, San Diego, CA, United States), utilizing a 600 cycle Nextera XT library kit. Trimmed Fastq data sets were *de novo* assembled using the recommended workflow on CLC Genomics Work bench version 8.0 (CLC bio, Aarhus, Denmark). Genomic contigs were annotated using the RAST annotation server ([@B4]). The assembled sequences were uploaded to the <http://www.genomicepidemiology.org/> server. Sequences of the seven housekeeping genes (*aroC, dnaN, hemD, hisD, purE, sucA* and *thrA*) were analyzed to identify multilocus sequence types (MLST)^[3](#fn03){ref-type="fn"}^, antibiotic resistance genes^[4](#fn04){ref-type="fn"}^, and plasmid replicon types^[5](#fn05){ref-type="fn"}^, using each website's algorithms and databases. Routine processing of genome datasets was carried out by in-house perl scripts (available upon request). A local customized database of *Salmonella* chromosomal and plasmid genomes from NCBI was created and used for annotation, plasmid analysis, and homology detection with BLAST suite ([@B1]). Phylogenetic analysis was conducted using a multiloci analysis based on a published core gene dataset ([@B18]). Alleles in 2780 core gene loci across all the genomes were identified with *Salmonella enterica* subsp. *enterica* serovar Typhimurium LT2 genome as the reference. Of these loci, 1,500 core gene loci were randomly chosen and alleles were concatenated. The data matrix of alleles was subject to multiple alignment and phylogenetic analysis using tools available in MEGA7 suite ([@B17]). The phylogenetic tree was built using the Neighbor-Joining algorithm in the MEGA 7 suite with 9,562 positions across 50 genomes for the final analysis.

For genome comparison, whole genome draft sequences of *Salmonella enterica* serovar Infantis strains from public databases were retrieved, including four recent strains of the prevalent Hungarian clone B of *S*. serovar Infantis from Hungary ([@B27], [@B28]), five *bla*~ESBL~ harboring, and eight non-*bla*~ESBL~ harboring strains from Italy, Israel and the United States. ([@B3]; [@B11]), and one fully susceptible strain from the United Kingdom ([@B24]). An overview of the strains and their GenBank accession numbers is given in **Table [1](#T1){ref-type="table"}**. For plasmid comparison, annotations were obtained from RAST ([@B4]), and compared with pCSAM042077 ([@B26]) on the SEED server for additional verification ([@B25]).

###### 

*S*. Infantis strains used for genome comparison in this study.

  Strain        Alias          Year of isolation   Region of isolation   Sample type   Source        GenBank accession no.   Reference
  ------------- -------------- ------------------- --------------------- ------------- ------------- ----------------------- -----------
  SI3337/12     3337 12 H      2012                Hungary               Animal        Broiler       MIJS00000000            [@B27]
  SI757/13      757 13 H       2013                Hungary               Animal        Broiler       MIJT00000000            [@B27]
  SI786/13      786 13H        2013                Hungary               Animal        Broiler       MIJR00000000            [@B27]
  SI1070/16     1070 16        2016                Hungary               Animal        Broiler       MRUX00000000            [@B28]
  13017779/5    brochM113      2013                Italy                 Animal        Broiler       ERR1014114              [@B11]
  12037823/11   brchM112       2012                Italy                 Animal        Broiler       ERR1014117              [@B11]
  13002124/1    huM12013       2013                Italy                 Clinical      Human         ERR1014112              [@B11]
  14026835      italy 2014     2014                Italy                 Clinical      Human         ERR1014119              [@B11]
  CFSAN042077   CFSAN042077    2015                United States         Food          Broiler       FSIS1502916             [@B26]
  120100        120100         2008                Israel                Food          Unknown       SAMN04217889            [@B2]
  119944        119944         2008                Israel                Clinical      Human         ASRF01000000            [@B3]
  07041415      broMESC07      2007                Italy                 Food          Broiler       ERR1014109              [@B11]
  09051564/79   broMESC09      2009                Italy                 Animal        Broiler       ERR1014118              [@B11]
  FDA00001200   CFSAN014765    2008                Israel                Food          Basil         SRR3453168              CFSAN^a^
  06029746      bromIEs6       2006                Italy                 Food          Broiler       ERR1014111              [@B11]
  335 3         335 3 israel   1970                Israel                Clinical      Human         SAMN02470973            [@B2]
  09051564/33   guifoIEc9      2009                Italy                 Animal        Guinea fowl   ERR1014110              [@B11]
  1326/28       infan649235    1973                United Kingdom        Animal        Broiler       SAMEA3106395            [@B24]

a

U.S. Food and Drug Administration's Center for Food Safety and Applied Nutrition

.

Results
=======

Antimicrobial Susceptibility Testing
------------------------------------

The distribution of resistance phenotypes among the *S*. serovar Infantis isolates is summarized in the **Table [2](#T2){ref-type="table"}** and shown in detail in technical Supplementary Tables [S1](#SM1){ref-type="supplementary-material"}--[S3](#SM3){ref-type="supplementary-material"}.

###### 

Origin and antimicrobial resistance characteristics among *S*. Infantis in Switzerland.

                      No. isolates with                            
  ------------- ----- ------------------- ------------ ----------- ------------
  2010          191                                                
        Food    167   64 (38.3%)          72 (43.1%)   4 (2.4%)    3 (1.8%)
        Human   19    2 (10.5%)           5 (26.3%)    0 (0%)      0 (0%)
        Other   5     2 (40%)             0 (0%)       0 (0%)      0 (0%)
  2013          161                                                
        Food    131   64 (48.9%)          32 (24.4%)   3 (2.3%)    7 (5.3%)
        Human   27    8 (29.6%)           8 (29.6%)    3 (11.1%)   1 (3.7%)
        Other   3     0 (0%)              0 (0%)       0 (0%)      0 (0%)
  2015          168                                                
        Food    120   31 (25.8%)          57 (47.5%)   6 (5%)      13 (10.8%)
        Human   38    14 (36.8%)          12 (31.6%)   4 (10.5%)   0 (0%)
        Other   10    4 (10%)             4 (10%)      0 (0%)      0 (0%)

a

NaSSuT, nalidixic acid-streptomycin-sulfamethoxazole-tetracycline resistance pattern.

b

NaSuT, nalidixic acid-sulfamethoxazole-tetracycline resistance pattern.

c

AMP, ampicillin.

d

CIP, ciprofloxacin

.

Multidrug resistant was detected in 389 (74.8%) of the isolates. Thereof, the majority (379/520, 72.9% of all isolates) showed a combined resistance pattern to nalidixic acid, sulfamethoxazole and tetracycline, with (NaSSuT) or without streptomycin (NaSuT). The NaSSut pattern was detected in 189 (36.3% of all isolates) and the NaSuT pattern in 190 (36.5% of all isolates). Resistance to ampicillin and ciprofloxacin was verified in 20 (3.8%) and 24 (4.6%) of the isolates, respectively, and showed a rising prevalence between 2010 and 2015 for both antimicrobials, as illustrated in **Figure [1](#F1){ref-type="fig"}**. A total of 496 (95.4% of all isolates) tested within the intermediate range for ciprofloxacin, according to CLSI breakpoints. An ESBL phenotype and growth on Brilliance^TM^ESBL agar was recorded for three strains (0.6% of all isolates), whereof two originated from humans (isolates 21-13 and 125-15) and one (isolate 144-13) from food (**Table [3](#T3){ref-type="table"}** and Supplementary Tables [S2](#SM2){ref-type="supplementary-material"}, [S3](#SM3){ref-type="supplementary-material"}).

![Percentage of *S*. serovar Infantis isolates with the nalidixic acid-sulfamethoxazole-tetracycline (NaSuT), or the nalidixic acid-streptomycin-sulfamethoxazole-tetracycline resistance pattern (NaSSuT) resistance pattern and resistance to ampicillin and ciprofloxacin in 2010, 2013 and 2015.](fmicb-08-01322-g001){#F1}

###### 

Characteristics of 32 sequenced *S*. Infantis from food, diseased humans and other sources from 2010, 2013 and 2015 from Switzerland.

  Strain ID   Year of isolation   Source   Phenotypic resistance pattern^a^   Resistance genes detected by WGS                                                                        ST              PFGE cluster   Accession no.
  ----------- ------------------- -------- ---------------------------------- ------------------------------------------------------------------------------------------------------- --------------- -------------- ---------------
  17-10       2010                Food     NaSSuT                             *aadA1*, *sul1*, *tetA*                                                                                 32              --             NAPL00000000
  78-10       2010                Human    NaSSuT                             *aadA1*, *sul1*, *tetA*                                                                                 32              C              NKQL00000000
  79-10       2010                Human    NaSSuT                             *aadA1*, *sul1*, *tetA*                                                                                 32              A              NAPI00000000
  111-10      2010                Other    Su                                 none                                                                                                    32              --             NAPF00000000
  115-10      2010                Food     NaSuT                              *aadA1*, *sul1*, *tetA*, *bla*~TEM-116~                                                                 32              --             NAPD00000000
  169-10      2010                Food     NaSuT                              *aadA1*, *sul1*, *tetA*                                                                                 32              B              NAOU00000000
  186-10      2010                Human    NaSuT                              *aadA1*, *sul1*, *tetA*                                                                                 32              D              NAOS00000000
  193-10      2010                Food     NaSSuT                             *aadA1*, *sul1*, *tetA*                                                                                 32              --             NAOR00000000
  21-13       2013                Human    NaSSuT, AMP, CTX                   *aph4-la*, *aadA1*, *aac3-IVa*, *aph3′-lc*, *bla*~CTX-M-65~, *fosA*, *floR*, *sul1*, *tetA*, *dfrA14*   32 variant^b^   --             NAPP00000000
  25-13       2013                Food     NaSSuT                             *aadA1*, *sul1*, *tetA*                                                                                 32              D              NAPO00000000
  31-13       2013                Food     NaSSuT                             *aadA1*, *sul1*, *tetA*                                                                                 32              --             NAPN00000000
  53-13       2013                Human    NaSuT                              *aadA1*, *sul1*, *tetA*                                                                                 32              E              NAPV00000000
  61-13       2013                Food     Su                                 none                                                                                                    32              --             NAPJ00000000
  100-13      2013                Food     none                               none                                                                                                    32              --             NAPU00000000
  112-13      2013                Food     NaSuT                              *aadA1*, *sul1*, *tetA*                                                                                 32              --             NAPE00000000
  123-13      2013                Food     NaSuT                              *aadA1*, *sul1*, *tetA*                                                                                 32              C              NAPB00000000
  133-13      2013                Food     NaSuT                              *aadA1*, *sul1*, *tetA*                                                                                 32              --             NAOY00000000
  144-13      2013                Food     NaSSuT, AMP, CTX                   *aph4-la*, *aadA1*, *aac3-IVa*, *aph3′-lc*, *bla*~CTX-M-65~, *fosA*, *floR*, *sul1*, *tetA*, *dfrA14*   32              --             NAOX00000000
                                                                                                                                                                                                                     
  153-13      2013                Human    Na, Su                             *aadA1*, *sul1*                                                                                         32              --             NAOV00000000
  173-13      2013                Human    NaSSuT                             *aadA1*, *sul1*, *tetA*                                                                                 32              C              NBAS00000000
  3-15        2015                Human    NaSSuT                             *aadA1*, *sul1*, *tetA*                                                                                 32              B              NAPW00000000
  15-15       2015                Human    NaSSuT                             *aadA1*, *sul1*, *tetA*                                                                                 32              A              NAPM00000000
  20-15       2015                Human    NaSuT                              *aadA1*, *sul1*, *tetA*                                                                                 32              --             NAPK00000000
  69-15       2015                Human    NaSuT                              *aadA1*, *sul1*, *tetA*                                                                                 32              --             NAPH00000000
  70-15       2015                Other    NaSuT                              *aadA1*, *sul1*, *tetA*, *floR*, *dfrA14*                                                               32              --             NKQM00000000
  97-15       2015                Human    NaSSuT                             *aadA1*, *sul1*, *tetA*                                                                                 32              --             NAPG00000000
  99-15       2015                Human    None                               None                                                                                                    32              --             NJAM00000000
  119-15      2015                Other    NaSSuT                             *aadA1*, *aph3'-lc*, *sul1*, *tetA*, *dfrA14*                                                           32              --             NAPC00000000
  125-15      2015                Human    NaSuT, AMP, CTX                    *aph4-la*, *aadA1*, *aac3-IVa*, *bla*~CTX-M-65~, *fosA*, *floR*, *sul1*, *tetA*, *dfrA14*               32              --             NAPA00000000
  126-15      2015                Human    None                               None                                                                                                    32              --             NAOZ00000000
  149-15      2015                Food     NaSuT                              *aadA1*, *sul1*, *tetA*                                                                                 32              --             NAOW00000000
  169-15      2015                Food     NaSSuT                             *aadA1*, *sul1*, *tetA*                                                                                 32              C              NAOT00000000

a

NaSSuT, nalidixic acid-streptomycin-sulfamethoxazole- tetracycline resistance pattern; NaSuT, nalidixic acid-sulfamethoxazole-tetracycline resistance pattern;

b

double-locus variant (

purE

288 and

sucA

565\) of ST32. AMP, ampicillin; CTX, cefotaxime; Na, nalidixic acid; PFGE, pulsed-field gel electrophoresis; Su, sulfamethoxazole; ST, sequence type; WGS, whole genome sequencing; --, isolate not belonging to any specific PFGE cluster. Resistance genes:
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,
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, phenicol;
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.

WGS
---

The genomic characteristics of the 32 genomes are listed in Supplementary Tables [S1](#SM1){ref-type="supplementary-material"}--[S3](#SM3){ref-type="supplementary-material"}. The average genome size, %G+C, and number of coding DNA sequences (CDS) of the isolates was 4.88 mbp (range:4.56--4.98 mbp), 52.2% (range: 52.1--52.3%), and 4812 CDS (range: 4443--4912 CDS), respectively.

Detection of Resistance Genes by PCR and by WGS
-----------------------------------------------

All three isolates displaying an ESBL phenotype showed the presence of the *bla*~CTX-M-65~ gene by PCR. WGS analysis using ResFinder confirmed the presence of the *bla*~CTX-M-65~ genes. All *bla*~CTX-M-65~-positive isolates carried other resistance genes *aph4-la*, *aadA1* and *aac3-IVa* (aminoglycoside resistance), *fosA* (fosfomycin resistance), *floR* (phenicol resistance), *sul1* (sulphonamide resistance), *tetA* (tetracycline resistance), and *dfrA14* (trimethoprim resistance) (**Table [3](#T3){ref-type="table"}** and Supplementary Tables [S2](#SM2){ref-type="supplementary-material"}, [S3](#SM3){ref-type="supplementary-material"}), while strains 21-13 and 144-13 also carried the *aph3′-lc* gene (aminoglycoside resistance). WGS of 23 MDR, non-ESBL producing isolates revealed the presence of *aadA1*, *sul1*, and *tetA* resistance genes throughout. Food isolate 115-10 additionally carried the non-ESBL *bla*~TEM-116~ gene. The environmental isolate 70-15 from Israel additionally harbored *floR* and *dfrA14* and MDR strain 119-15 isolated from animal feed also carried *aph3′-lc* and *dfrA14* (**Table [3](#T3){ref-type="table"}** and Supplementary Table [S3](#SM3){ref-type="supplementary-material"}).

Whole genome sequencing did not detect any resistance genes in six non-MDR isolates (**Table [3](#T3){ref-type="table"}** and Supplementary Tables [S1](#SM1){ref-type="supplementary-material"}--[S3](#SM3){ref-type="supplementary-material"}), except for human isolate 153-13 which showed intermediate resistance to streptomycin and harbored *aadA1* and *sul1* (**Table [3](#T3){ref-type="table"}** and Supplementary Table [S2](#SM2){ref-type="supplementary-material"}).

Detection of Plasmids and Replicon Types among the Isolates
-----------------------------------------------------------

By mapping WGS assemblies to the 320 kb plasmid pCFSAN42077 from *bla*~CTX-M-65~ carrying food isolate CFSAN42077 ([@B26]), contigs or regions similar to this plasmid in isolates 21-13, 144-13 and 125-15 were detected (data not shown). Specific contigs bearing the *bla*~CTX-M-65~ gene and surrounding loci were identified (**Figure [2](#F2){ref-type="fig"}**). The ∼5 kb cassette consisted of *bla*~CTX-M-65~ followed by an IS5/IS1182 family transposase and a gene encoding a TonB-dependent siderophore receptor. The 5′-end is flanked by an IS6 family transposase upstream of the *fipA* gene, which is truncated in pCFSAN42077. By comparison, *fipA* is absent in p14026835, a *bla*~CTX-M-65~ harboring plasmid from human *S*. Infantis isolate 14026835 from Italy (ERR1014119), as shown in **Figure [2](#F2){ref-type="fig"}**. As predicted, no replicons were detected in the genomes of these three *bla*~CTX-M-65~ harboring isolates ([@B11]).

![Multiple sequence alignment with pCSAM042077 from *S*. Infantis from food from the United States (FSIS150291), of a *bla*~CTX-M-65~ cassette on putative ∼320 kb plasmids from three *S*. Infantis strains from food (144-13) and diseased humans (21-13 and 125-15) from Switzerland and one *S*. Infantis strain from Italy (ERR1014119). The ∼5 kb cassette consists of *bla*~CTX-M-65~ followed by an IS5/IS1182 family transposase and a gene encoding a TonB-dependent siderophore receptor, and one or two hypothetical genes. The cassette is flanked on either side by the IS6 transposase. The *fipA* gene is of varied lengths, or absent.](fmicb-08-01322-g002){#F2}

For other isolates in this study, WGS analysis showed the presence of incompatibility group IncFII (p96A) plasmid (accession \#JQ418521), in the fully susceptible human isolate 99-15 (N15-1280), Incl1 (accession \#AP005147) in fully susceptible food isolate 100-13 (N13-1368), and pESA2 and IncFII (pCTU2) (accession nos. \#CP000784 and \#FN543095, respectively) in fully susceptible human isolate 126-15 (N15-1729) (data not shown).

PFGE Cluster Analysis, MLST and Phylogenetic Analysis
-----------------------------------------------------

### PFGE

Pulsed-field gel electrophoresis analysis revealed 190 distinct *XbaI* restriction patterns (all patterns are available upon request). Of the 520 isolates, 270 (51.9%) shared a similarity of 90%. Five clusters A--E showing a similarity of \>93% and consisting of 121 (23.3% of total) isolates were detected. Isolates within a cluster had indistinguishable profiles. The clusters A--E contained 21 (4% of the total), 18 (3.5%), 27 (5.2%), 43 (8.3%) and 12 (2.3%) isolates, respectively. Isolates from sources other than human infections or food (e.g., environmental samples) were not detected within these clusters.

### MLST and Phylogenetic Analysis

All 32 isolates subjected to WGS belonged to sequence type (ST) ST32, except isolate 21-13, which was a double-locus variant (*purE* and *sucA*) of ST32 (**Table [3](#T3){ref-type="table"}**).

Genetic relatedness was investigated by mapping the 32 genomes to the genome sequences of isolates belonging to the Hungarian clone B from broilers, the *bla*~ESBL~, and non-*bla*~ESBL~ harboring strains from Italy, Israel and United States. The resulting unrooted phylogenetic tree is shown in **Figure [3](#F3){ref-type="fig"}**. The isolates segregated into eight major clusters. Clusters determined by PFGE and by WGS did not correlate.

![Core gene analysis based phylogeny of 32 selected *S*. serovar Infantis from food, diseased humans and environmental sources from 2010, 2013 and 2015 from Switzerland and of *S*. serovar Infantis from Hungary, Israel, Italy and United States. Alleles from 1500 randomly chosen core genes from more than 2770 conserved loci were used to build a phylogenetic tree. The data matrix of alleles was subject to multiple alignments. The phylogenetic tree was built using the Neighbor-Joining algorithm in the MEGA 7 suite with 9,562 positions across 50 genomes for the final analysis. Bar indicates 20 single nucleotide polymorphisms (SNP). Blue box: Isolates belonging to the Hungarian clone. Red box: Isolates harboring *bla*~CTX-M-65~.](fmicb-08-01322-g003){#F3}

Close phylogenetic relatedness with strains 3337 12 H, 757 13 H, 786 13H, 1070 16 belonging to the Hungarian clone B was detected in seven (21.9%) of the sequenced strains and included human and food isolates from 2010, 2013 and 2015 (**Figure [3](#F3){ref-type="fig"}**). The *bla*~CTX-M-65~ harboring isolates 21-13, 144-13 and 125-15 were more distantly related to the isolates that clustered with the Hungarian clone B. All three isolates were closely related to, and formed a distinct cluster with the *bla*~CTX-M-65~ harboring human isolate (italy 2014) from Italy and the food isolate CFSAN 042077 from the United States.

Four (12.5%) of the genomes (isolates 15-15, 169-10, 112-13 and 133-13, respectively) grouped in a distinct cluster with non-*bla*~ESBL~, pESI-like harboring strains isolated previously from broiler meat in Italy. One environmental isolate (isolate 70-15) originating from Israel formed a cluster with three strains from Israel (pESI containing 120100 and 119944, and CFSAN014765). Two fully susceptible isolates (63-13 and 126-15) were placed in the phylogenetic tree together with the non-pESI containing strain 335 3 isolated in Israel in 1971 (**Figure [3](#F3){ref-type="fig"}**).

Accession Numbers
-----------------

The accession numbers of the 32 sequenced isolates are listed in **Table [3](#T3){ref-type="table"}** and Supplementary Tables [S1](#SM1){ref-type="supplementary-material"}--[S3](#SM3){ref-type="supplementary-material"}. This Whole Genome Shotgun project has been deposited at DDBJ/ENA/GenBank under the accession [NAOX00000000](NAOX00000000). The version described in this paper is version [NAOX00000000.1](NAOX00000000.1).

Discussion
==========

*S*. serovar Infantis has emerged as an important disseminator of MDR in the food chain, representing a threat to human health ([@B23]). The majority of strains in this study exhibited either the NaSuT pattern or the characteristic NaSSuT pattern previously identified in the MDR *S*. Infantis clone B that emerged in broilers in farms in Hungary and subsequently spread within and outside of Europe, including to the countries of Poland, Austria, Germany, Israel and Japan ([@B14]; [@B23]). WGS performed in this study detected clonality in strains deemed different by PFGE and provides evidence that the Hungarian clone B has persisted since at least 2010 in Switzerland within the food chain and is associated with human disease. Strains belonging to three other closely related clusters were less prevalent but showed similar resistance patterns and persistence within food and human isolates.

In addition, we observed the occurrence of *S*. serovar Infantis harboring *bla*~CTX-M-65~. This *bla* gene has been detected previously in one human *S*. serovar Infantis isolate in Great Britain and in one from Italy ([@B6]), and furthermore, in an outbreak of *S*. Infantis in Ecuador ([@B7]), as well as in food in the United States. The results presented in this study show that the *bla*~CTX-M-65~ harboring *S*. serovar Infantis from Switzerland belong to a unique lineage but are similar to the strains from Italy and the United States, suggesting the emergence of a *bla*~CTX-M-65~ harboring, MDR *S.* serovar Infantis lineage in Europe as well as in North and South America. Moreover, this study shows that this lineage has been present in food and humans at least as early as 2013 in Europe.

Whole genome sequencing of these strains indicate the presence of a ∼320 kb plasmid similar to the pESI plasmid, a megaplasmid carrying multiple resistance and virulence genes originally detected in *S*. serovar Infantis in Israel in 2008 ([@B3]). In addition, resistance genes *drfA14* and *fosA* (trimethoprim and phenicol resistance genes, respectively) which are also found on pESI-like plasmids ([@B11]), were detected in all *bla*~CTX-M-65~ harboring strains. Several other non-*bla*~ESBL~ harboring strains from this study had a close phylogenetic-relatedness to strains from Israel and Italy which harbor non-*bla*~ESBL~ pESI or pESI-like plasmids ([@B3]), suggesting that certain *S*. serovar Infantis clones or lineages are acquiring these plasmids independently.

Our results correlate with the recent detection of a clone harboring a pESI-like plasmid and the *bla*~CTX-M-1~ gene in the broiler industry and humans in Italy ([@B11]), and suggest that some *S*. serovar Infantis clones harboring pESI-like plasmids may be undergoing a microevolution by acquiring *bla*~ESBL~ genes. While in Europe *bla*~CTX-M-1~ is prevalent within the poultry industry and has been well documented ([@B31]), *bla*~CTX-M-65~ has rarely been described. By contrast, it is a prevalent *bla*~ESBL~ gene in animal and human *E. coli* strains and *S*. serovar Indiana isolates in China ([@B5]), from where it may have disseminated via horizontal transfer. However, further studies are needed to clarify the origins of this *bla*~ESBL~ gene and to characterize and compare the plasmids carrying *bla*~ESBL~ genes in *S*. serovar Infantis.

The emergence of MDR *S*. Infantis with resistance to third generation cephalosporins in food and in humans is of great concern, particularly since these strains show intermediate resistance to ciprofloxacin. The use of fluoroquinolones for the treatment of infections caused by such strains may be associated with unfavorable treatment outcomes and the selection of high-level ciprofloxacin resistance ([@B15]).

This study extends our knowledge on clones of *S*. serovar Infantis circulating in food and causing disease in humans and provides evidence for the emergence of an MDR, ESBL-producing clone harboring *bla*~CTX-M-65~ in Switzerland. Our results highlight the necessity of strategies to reduce the prevalence of *S*. serovar Infantis within the food producing industry.
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